CYRAMZA
ramucirumab
- Strength
- 10 mg/mL
- Form
- Solution
- Class
- Vascular Endothelial Growth Factor Rece…
Eli Lilly and Company
Not stocked by us — reference only
ramucirumab
Listed by Eli Lilly and Company
| Dosage form | Solution |
|---|---|
| Route | Intravenous |
| Drug class | Vascular Endothelial Growth Factor Receptor 2 Antagonist |
| Approval route | BLA — biologic licence |
| NDC code | 0002-7678 |
| FDA application | BLA125477 |
| RxNorm concept | 1657775 |
| Package sizes listed | 1 |
| Marketed since | April 2014 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
ramucirumab
Eli Lilly and Company
Not stocked by us — reference only
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.